Literature DB >> 2336342

Pharmacokinetics of baclofen in spastic patients receiving multiple oral doses.

E W Wuis1, M J Dirks, T B Vree, E Van der Kleijn.   

Abstract

The pharmacokinetics of racemic baclofen as determined from plasma and urine data in six spastic patients treated with individualized oral doses, 30-80 mg daily, are presented. Peak plasma concentrations were achieved 1.9 h (+/- 0.7) after a dose. The fluctuation in the plasma concentration was great, ranging from 188 to 439%. The total body clearance averaged 175 ml.min-1 (+/- 44), plasma protein binding 35% (+/- 6). Baclofen was for the greater part excreted unchanged by the kidney, 65% (+/- 16). Its apparent renal equalled the creatinine clearance. The contribution of the renal clearance to the total body clearance can explain the previously described toxicity when renal impairment is present. The results agree with earlier reports on single doses in healthy subjects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2336342     DOI: 10.1007/bf01970149

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  15 in total

1.  Rapid simultaneous determination of baclofen and its gamma-hydroxy metabolite in urine by high-performance liquid chromatography with ultraviolet detection.

Authors:  E W Wuis; L E van Beijsterveldt; R J Dirks; T B Vree; E van der Kleyn
Journal:  J Chromatogr       Date:  1987-09-04

2.  Periodic sharp waves in baclofen-induced encephalopathy.

Authors:  J T Hormes; E E Benarroch; M Rodriguez; D W Klass
Journal:  Arch Neurol       Date:  1988-07

3.  Pharmacokinetics in baclofen overdose.

Authors:  P Anderson; H Nohér; C G Swahn
Journal:  J Toxicol Clin Toxicol       Date:  1984-07

4.  Adverse effects secondary to baclofen withdrawal.

Authors:  S M Garabedian-Ruffalo; R L Ruffalo
Journal:  Drug Intell Clin Pharm       Date:  1985-04

Review 5.  Drug therapy: spasticity (second of two parts).

Authors:  R R Young; P J Delwaide
Journal:  N Engl J Med       Date:  1981-01-08       Impact factor: 91.245

6.  Baclofen toxicity associated with declining renal clearance after ibuprofen.

Authors:  P A Dahlin; J George
Journal:  Drug Intell Clin Pharm       Date:  1984-10

7.  The pharmacokinetics of baclofen derived from intestinal infusion.

Authors:  G M Kochak; A Rakhit; W E Wagner; F Honc; L Waldes; R A Kershaw
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

8.  Baclofen in the elderly stroke patient its side-effects and pharmacokinetics.

Authors:  A Hulme; W J MacLennan; R T Ritchie; V A John; P A Shotton
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Plasma and urinary excretion kinetics of oral baclofen in healthy subjects.

Authors:  E W Wuis; M J Dirks; E F Termond; T B Vree; E Van der Kleijn
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

10.  Intrathecal baclofen for severe spinal spasticity.

Authors:  R D Penn; S M Savoy; D Corcos; M Latash; G Gottlieb; B Parke; J S Kroin
Journal:  N Engl J Med       Date:  1989-06-08       Impact factor: 91.245

View more
  9 in total

1.  Discovery of a Negative Allosteric Modulator of GABAB Receptors.

Authors:  Lin-Hai Chen; Bing Sun; Yang Zhang; Tong-Jie Xu; Zhi-Xiong Xia; Jian-Feng Liu; Fa-Jun Nan
Journal:  ACS Med Chem Lett       Date:  2014-05-27       Impact factor: 4.345

2.  Human pharmacokinetics of the muscle relaxant, eperisone hydrochloride by liquid chromatography-electrospray tandem mass spectrometry.

Authors:  Barbara Melilli; Cateno Piazza; Daniela Cristina Vitale; Maria Rosa Marano; Andrea Pecori; Paolo Mattana; Valentina Li Volsi; Carmelo Iuculano; Francesco Cardì; Filippo Drago
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-03-30       Impact factor: 2.441

3.  Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy.

Authors:  Yang He; Janice E Brunstrom-Hernandez; Liu Lin Thio; Shellie Lackey; Deborah Gaebler-Spira; Maxine M Kuroda; Elaine Stashinko; Alexander H Hoon; Jilda Vargus-Adams; Richard D Stevenson; Stephanie Lowenhaupt; John F McLaughlin; Ana Christensen; Nienke P Dosa; Maureen Butler; Aloysia Schwabe; Christina Lopez; Desiree Roge; Diane Kennedy; Ann Tilton; Linda E Krach; Andrew Lewandowski; Hongying Dai; Andrea Gaedigk; J Steven Leeder; William J Jusko
Journal:  J Pediatr       Date:  2014-03-05       Impact factor: 4.406

4.  Baclofen has opposite effects on escalation of cocaine self-administration: increased intake in rats selectively bred for high (HiS) saccharin intake and decreased intake in those selected for low (LoS) saccharin intake.

Authors:  Nathan A Holtz; Marilyn E Carroll
Journal:  Pharmacol Biochem Behav       Date:  2011-09-06       Impact factor: 3.533

5.  Iatrogenic Baclofen Neurotoxicity in ESRD: Recognition and Management.

Authors:  John K Roberts; Scott Westphal; Matthew A Sparks
Journal:  Semin Dial       Date:  2015-06-21       Impact factor: 3.455

6.  Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease.

Authors:  A F Ciccaglione; L Marzio
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

7.  Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans.

Authors:  Raymundo Sanchez-Ponce; Li-Quan Wang; Wei Lu; Jana von Hehn; Maryann Cherubini; Roger Rush
Journal:  Metabolites       Date:  2012-09-11

8.  Full-Profile Pharmacokinetic Study of High Dose Baclofen in Subjects With Alcohol Use Disorder.

Authors:  Nicolas Simon; Romain Moirand; Maurice Dematteis; Régis Bordet; Dominique Deplanque; Benjamin Rolland
Journal:  Front Psychiatry       Date:  2018-08-23       Impact factor: 4.157

Review 9.  Pharmacokinetic Studies of Baclofen Are Not Sufficient to Establish an Optimized Dosage for Management of Alcohol Disorder.

Authors:  Nicolas Simon; Nicolas Franchitto; Benjamin Rolland
Journal:  Front Psychiatry       Date:  2018-10-05       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.